Poly(anhydride-co-imides): in vivo biocompatibility in a rat model.
The degradation and tissue compatibility characteristics of a novel class of biodegradable poly(anhydride-co-imide) polymers: poly[trimellitylimidoglycine-co-1,6-bis(carboxyphenoxy)hexan e] (TMA-gly: CPH) (in 10:90; 30:70 and 50: 50 molar ratios) and poly[pyromellitylimidoalanine-co-1,6-bis(carboxyphenoxy)hexa ne] (PMA-ala:CPH) (in 10:90 and 30:70 molar ratios) were investigated and compared with control poly(lactic acid/glycolic acid) (PLAGA in 50:50 molar ratio) matrices, a well-characterized biocompatible polymer, in rat subcutaneous tissues for 60 days. Polymers were compression-molded into circular discs of 14 mm x 1 mm in diameter. On post-operative days 7, 14, 28 and 60, histological tissue samples were removed, prepared by fixation and staining, and analyzed by light microscopy. PLAGA matrices produced mild inflammatory reactions and were completely degraded at the end of 60 days, leaving implant tissues that were similar to surgical wounds without implants. TMA-gly:CPH (10:90 and 30:70) matrices produced mild inflammatory reactions by the end of 60 days, similar to those seen with PLAGA. TMA-gly: CPH (50: 50) produced moderate inflammatory reactions characterized by macrophages and edema. PMA-ala:CPH matrices elicited minimal inflammatory reactions that were characterized by fibrous encapsulation by the end of 60 days. In vivo degradation rates of poly(anhydride-co-imides) were similar to PLAGA. Both PMA-ala:CPH and TMA-gly: CPH matrices maintained their shapes and degraded at a constant rate over the period of two months. These polymers, possessing good mechanical properties and tissue compatibility, may be useful in weight-bearing applications in bone.
Department of Biology, Morris Brown College, Atlanta, GA, USA.
S M
SM
Ibim
K E
KE
Uhrich
R
R
Bronson
S F
SF
El-Amin
R S
RS
Langer
C T
CT
Laurencin
D000210:Acute-Phase Reaction / Q000139:chemically induced; D000818:Animals; D001672:Biocompatible Materials / Q000494:pharmacology* / Q000633:toxicity; D006586:Hexanes / Q000494:pharmacology* / Q000633:toxicity; D019344:Lactic Acid / Q000494:pharmacology / Q000633:toxicity; D008264:Macrophages / Q000473:pathology; D008297:Male; D009504:Neutrophils / Q000473:pathology; D010587:Phagocytosis; D011100:Polyglycolic Acid / Q000494:pharmacology / Q000633:toxicity; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000494:pharmacology* / Q000633:toxicity; D019736:Prostheses and Implants; D051381:Rats; D017207:Rats, Sprague-Dawley; D012867:Skin / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D013997:Time Factors
D001672:Biocompatible Materials; D006586:Hexanes; D011108:Polymers; C115154:poly(pyromellitylimidoalanine-co-1,6-bis(carboxyphenoxy)hexane); C115155:poly(trimellitylimidoglycine-co-1,6-bis(carboxyphenoxy)hexane); D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid